Acroscell Develops Cardiac Ion Channel Screen Panels to Accelerate Early Stage Drug Development

June 02 09:33 2022
Creative Bioarray announced the release of its cardiac ion channel screen panels in order to accelerate early stage drug development.

New York, USA – June 1, 2022 – Acroscell, the electrophysiology platform of Creative Bioarray, is dedicated to offering an innovative, time-efficient, cost-effective and comprehensive range of preclinical R&D services specialized in but not limited to cardiovascular & neural system physiological/pathophysiological mechanisms with strong scientific support. Recently, Creative Bioarray announced the release of its cardiac ion channel screen panels in order to accelerate early-stage drug development.

Drug-induced cardiovascular complications limit the use of many successful clinical treatments such as anticancer therapy. Most drug-induced cardiovascular complications include significant cardiac insufficiency as well as some negative effects such as hypertension, ischemia, and arrhythmias.

One of the most important cardiovascular (CVS) issues in safety pharmacology is a life-threatening disease called torsades de pointes (TdP), which is dominated by changes in the activity of hERG (Kv11.1) channels and other important cardiac ions Mediating channels (Cav1.2, Nav1.5, Kv4.3, Kir2.1 and Kv7.1). Many compounds can affect the activity of ion channels or transporters and thus have the potential to delay ventricular repolarization and lead to QT interval prolongation.

Creative Bioarray has a team of experts with years of experience in ion channel safety testing and cardiotoxicity assessment, providing electrophysiological services for in vitro (eg hERG safety) assays and in vivo (eg QT assays for ECG) assays. Creative Bioarray has developed a GLP-compliant in vitro electrophysiology service that provides clients with a robust ion channel platform for characterizing the mechanism of action and safety of lead compounds. This in vitro cardiac profile screen provides a comprehensive safety analysis, including inhibition testing and IC50 metrics.

Leveraging traditional patch clamp and MEA techniques, Creative Bioarray can provide services to detect and analyze the effects of drug candidates on key cardiac ion channels and pathways with predictable and reproducible data. Creative Bioarray now offers the Cardiac Safety Panel, which conducts tests to determine drug interactions with cardiac ion channels that are targets of QT prolongation. The Cardiac Ion Channels panel from Creative Bioarray can help minimize the unnecessary sorting of promising compounds.

“We have developed an automated QPatch-HT system that provides our customers with analytical results with better consistency and lower cost. In addition, we also offer routine whole-cell patch-clamp assays for hERG safety testing in accordance with ICH S7B guidelines.” said Hannah Cole, the marketing director of Creative Bioarray, she also added, “we are capable to provide customized solutions in order to satisfy specific requirements for individual programs.”

About Acroscell

As a mature division of Creative Bioarray, Acroscell definitely will be the ideal and reliable innovation partner in research endeavors. With the support of professional scientists and years of experience, We are capable to provide a knowledgeable, collaborative and flexible service to our clients so as to accelerated drug development and improve research quality for worldwide projects.

Media Contact
Company Name: Creative Bioarray
Contact Person: Hannah Cole
Email: Send Email
Phone: 1-631-386-8241
Country: United States